Are These Presidential Penny Stocks On Your Watch List Right Now?
This is the week we’ve been waiting for and penny stocks will certainly one of the things on the menu. Everything from health care to marijuana legalization is in the spotlight this week. Not that it wasn’t before, but, for obvious reasons, these are becoming some hot topics among traders in the stock market today.
The typical volatility we’ve seen in the stock market has a great chance of increasing during at least the first half of the week. The general consensus: the election could see a contested result no matter the outcome. Since the market inherently dislikes uncertainty, what more could you ask for in such a situation.
[Read More] How To Invest In Penny Stocks Online
A few things to also discuss, outside of the U.S. election. First, there’s a new wave of lockdowns in place across Europe due to rising coronavirus cases. What’s more is that there’s pretty much no chance we are going to see a vaccine “before the election”. Again, uncertainty can play a huge role. a partial shutdown Monday in Germany, as authorities across the continent scramble to slow a rapid rise in coronavirus infections that threatens to overwhelm their health care systems.
“We are aware of the frustration, the sense of loss, the tiredness of citizens, also of the anger which is being manifested in these days, by citizens who find themselves living with new limits to their personal freedom.”Italian Premier Giuseppe Conte
In any case, this is likely to be a busy week and one full of new opportunities. Will these names be on your list of penny stocks to watch?
Penny Stocks To Watch: GT Biopharma Inc.
GT Biopharma Inc. (GTBP Stock Report) is one of the more active cancer stocks to watch this quarter. Over the last few weeks, the company has made several key advancements in its treatment pipeline. This includes both with one of its lead treatments and with its base treatment technology, TriKE. It’s a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially. It has led to new first-in-human phase studies to treat leukemia. It’s further been evaluated in ovarian, breast, prostate, pancreatic ductal adenocarcinoma and lung cancer models. The company has set a goal of designing TriKE as a true off the shelf option for numerous different cancer indications.
Toward the end of October, GT announced the publication of “NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo”. This was in the journal Cancers. The research effort was conducted by researchers at the University of Minnesota and at Massachusetts General Hospital/Harvard Medical School. According to GT, this B7H3 protein is highly expressed on the surface of several types of cancer.
Based on the findings, GT saw that a B7H3-targeted TriKE could enhance natural killer cell immunotherapy in solid tumor settings. This further justified the advancement of a B7H3 TriKE to clinical development.
Considering the attention that cancer and immunotherapy stocks are receiving right now, GTBP has remained one to watch during the 4th quarter of 2020.
Penny Stocks To Watch: Anpac Bio Medical Science
Anpac Bio Medical Science (ANPC Stock Report) is one of the biotech penny stock jumping during premarket hours on Monday. The company focuses on early-stage cancer screening and detection. Starting things off for election week, ANPC shares jumped to early highs of over $5 on Monday.
[Read More] Top Penny Stocks To Buy Now According To Analysts; 1 Up 250%+ In 2020
This was thanks to the company’s most recent update. Anpac announced that its investee company in China, Jiangsu AnPac Health Management Co., Ltd. qualified for COVID-19 nucleic acid tests in the first half of 2020. Furthermore, it received certification from the regulatory authority on October 17, 2020, for COVID-19 nucleic acid tests in Jiangsu AnPac’s medical lab in the City of WuXi, Jiangsu Province, China.
“In addition to a successful launch of our immunology test product in the first half year, the qualification and commercialization of COVID-19 tests is another major achievement for AnPac Bio this year.”AnPac Bio’s CEO, Dr. Chris Yu
The company explained that Jiangsu AnPac has started receiving samples for paid COVID-19 nucleic acid tests. AnPac Bio and Jiangsu AnPac inked a deal to create and qualify new COVID-19 test technologies and products. Obviously, coronavirus remains a major topic of discussion. How things will play out after the election is still yet to be seen. However, as cases increase, testing and treatment are at the forefront.
Penny Stocks To Watch: BioLineRx Ltd.
Last week we discussed BioLineRx Ltd. (BLRX Stock Report) following a major update from the company. It ended up acting as a catalyst for a large move in the penny stock. Quite literally overnight, BLRX stock jumped over 100%. BioLineRx announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial. This was of its motixafortide for stem cell mobilization in multiple myeloma patients.
The company explained that the results were favorable. This form of treatment represented a “significant unmet medical need” in multiple myeloma. “The compelling results of this planned interim analysis are a very significant milestone for our Company, as our SCM program is the Company’s most efficient path to registration for motixafortide,” stated Philip Serlin, Chief Executive Officer of BioLineRx.
- 5 Best Penny Stocks To Watch Right Now If Biotech Is Your Focus
- Top 5 Penny Stocks On Robinhood For November 2020
- Looking For Penny Stocks To Buy In November 2020? 3 To Watch, Now
In addition to these results, the company also began a new trial. This was a Phase 2 trial for metastatic pancreatic cancer. The company’s lead drug candidate, the CXCR4-inhibitor Motixafortide, will be tested in combination with LIBTAYO® and standard-of-care chemotherapy. Data isn’t expected until 2022. But like most biotech companies, traders will likely keep an eye out for any developments along the way.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), GT Biopharma is required to pay $200,000 per month for 4 months of services, $400,000 of which has already been paid for 2 months of services (first and last month) for a period from September 22, 2020 to January 22, 2021. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).